Thursday, December 18, 2025 12/18/2025

Identification of CNS-Penetrant Tryptophan 2,3-Dioxygenase Degrading Ligands

Award Number: R21AG078775
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2025

Group Awards By:

View Award Description

Identification of CNS-Penetrant Tryptophan 2,3-Dioxygenase Degrading Ligands - ABSTRACT Tryptophan 2,3-dioxygenase (TDO) is a key modulator of physiological neurogenesis and anxiety-related behavior. Misregulated neuronal TDO activity causes elevated levels of tryptophan-kynurenine pathway metabolites, which in turn, causes depression, brain degeneration, and neurodegenerative Alzheimer's, Parkinson's, and Huntington's diseases. However, a critical need remains for identifying new agents that function through innovative mechanisms to probe a range of pharmacological hypotheses regarding central TDO action, ultimately advancing our overall pharmacological knowledge, and to also serve as leads for downstream medicinal chemistry optimization, thus helping people live long healthy lives. To identify innovative inhibitors, we engaged in a joint basic science-clinical study that identified a non-catalytic L-tryptophan (L-Trp) binding site in human TDO that binds L-Trp surprisingly much tighter than the catalytic heme site. The newly discovered L-Trp binding site is involved in regulating TDO activity and stability by suppressing ubiquitin-dependent degradation when loaded with L-Trp. This finding has inspired us to propose a central hypothesis that this newly discovered signaling site is an Achilles' heel of TDO for drug development. This application will fill the critical need to identify CNS-penetrant protein-degrading ligands for exploring their biomedical potential. Towards this end, we will employ our rigorous understanding of the underlying chemistry and biology to design compounds with a novel mode of action that destabilize the signaling site of TDO or bind without enhancing the protein stability. These agents will not target the catalytic activity of TDO but instead will disrupt its degradation resistance signal. We will assess the effects of promising compounds on human TDO in cellular models to validate the innovative approach and target. In the end, this work will open the door for designing revolutionarily new centrally-active inhibitors targeting human TDO.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$3,633 )
2026	2023	PURDUE UNIVERSITY	2550 NORTHWESTERN AVE # 1100	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Aging Research	000	2	12/8/2025	NON-COMPETING CONTINUATION	-$3,633
														Subtotal = -$3,633

Issue Date FY: 2023 ( Subtotal = $184,651 )
2023	2023	PURDUE UNIVERSITY	2550 NORTHWESTERN AVE STE 1900	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Aging Research	000	2	6/15/2023	NON-COMPETING CONTINUATION	$184,651
														Subtotal = $184,651

Issue Date FY: 2022 ( Subtotal = $235,901 )
2022	2022	PURDUE UNIVERSITY	2550 NORTHWESTERN AVE STE 1900	WEST LAFAYETTE	IN	47906	TIPPECANOE	USA	Aging Research	000	1	8/24/2022	NEW	$235,901
														Subtotal = $235,901

Grand Total All Awards = $416,919

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identification of CNS-Penetrant Tryptophan 2,3-Dioxygenase Degrading Ligands

Award Number: R21AG078775

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer